During Monday’s trading session, the shares of a company engaged in the business of contract manufacturing of formulation for pharmaceutical companies surged nearly 4.3 percent on NSE, after announcing that it will manufacture and supply oncology products for Intas’ subsidiary in the UK, EU, and emerging markets.
Price Movement
With a market capitalisation of Rs. 522.4 crores, at 01:43 p.m., the shares of Sakar Healthcare Limited were trading at Rs. 238, up by nearly 0.7 percent, as compared to its previous closing price of Rs. 236.35.
The stock has delivered negative returns of nearly 38 percent in the last one year, as well as around 21 percent returns in the last one month.
What’s the News
According to the latest regulatory filings with the NSE, Sakar Healthcare will manufacture and supply oncology products for ACCORD Healthcare Limited, a wholly-owned subsidiary of lntas Pharmaceuticals, in the EU, UK and emerging markets.
Sakar is set to provide oncology injections and oral solid products to ACCORD, serving the UK and EU countries.
The technology transfer process has already begun for seven oncology products (5 oral solids and 2 injections) that are registered at Sakar’s research-driven, API-integrated, EU GMP-approved manufacturing facility for oncology finished dosage formulations.
This strategic move is expected to boost Sakar’s oncology product supply in the EU and UK markets, along with the registration of products under its own name.
ACCORD Healthcare Limited, ranked amongst the top three in most EU markets with a strong portfolio of anti-cancer products, operating in over 45 countries with a major focus and supply of generic oncology products covering hospitals and retail pharmacies across Europe and the rest of the world.
Also read: Solar stock jumps over 4% after receiving order for supply of 200MW+ solar inverters
Financials
Sakar Healthcare reported a significant growth in revenue from operations, experiencing a year-on-year increase of nearly 16.6 percent, rising from Rs. 37.23 crores in Q3 FY24 to Rs. 43.4 crores in Q3 FY25.
Likewise, during the same period, the company’s net profit increased from Rs. 2.07 crores to Rs. 4.5 crores, representing an impressive growth of around 117.4 percent YoY.
About the Company
Sakar Healthcare Limited is engaged in the manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectables (SVP) in ampoules, vials & lyophilized injections, oral solid dosages and research & development of above products.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
